Zomedica Corp. - ZOM STOCK NEWS

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) held its 2020 Annual and Special Virtual-Only Meeting, where shareholders elected a new board of directors and approved several proposals, including the appointment of MNP LLP as auditors and amendments to company articles. Notably, a proposed reverse stock split was approved by majority but fell short of the two-thirds majority needed under Canadian law. The company reports approximately $50 million in cash, highlighting readiness for advancing its lead product, TRUFORMA™, while exploring listing options on major exchanges.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced that its proxy solicitor, Alliance Advisors, mailed a letter urging shareholders to vote on Proposal 3 at the upcoming Annual and Special Virtual-Only Meeting on September 25, 2020. The proposal involves a reverse stock split at a ratio of 1-for-25 to 1-for-50, aimed at increasing the share price to maintain its NYSE listing. The company warns that failing to maintain this listing could result in a shift to over-the-counter trading, negatively impacting share liquidity and value. Shareholders are encouraged to vote their shares.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced that Robert Cohen, Interim CEO, and Stephanie Morley, President and CMO, will present at the H.C. Wainwright Virtual Global Investment Conference on September 14, 2020, at 4:00 pm ET. The presentation slides will be available on the company's website on the morning of the event. Zomedica focuses on creating innovative veterinary diagnostic products for companion animals, addressing unmet needs in veterinary care to enhance productivity and revenue for clinical veterinarians.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has partnered with Qorvo Biotechnologies to develop three canine diagnostic assays for gastrointestinal issues: Cobalamin, cPL, and Folate. This initiative triggers a $2 million milestone payment under their agreement. These assays will enhance the TRUFORMA platform, enabling veterinarians to perform comprehensive gastrointestinal testing at the point-of-care, potentially improving diagnosis and treatment speed. The BAW sensor technology used in TRUFORMA promises laboratory-level accuracy, addressing a significant market need as GI conditions are common pet insurance claims.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) shares updates on its lead product, TRUFORMA, in a letter from Interim CEO Robert Cohen. With over US $50 million in cash, Zomedica aims to launch TRUFORMA with five assays, verified in partnership with Qorvo. The letter emphasizes rigorous validation and testing processes, and a hybrid sales model involving regional distributors and direct sales staff. Shareholder approval for a proposed reverse stock split is sought to comply with NYSE American requirements. Cohen expresses optimism about the company's future amidst ongoing challenges, including COVID-related adjustments.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) reported its second quarter financial results for the period ending June 30, 2020. The company posted a net loss of $5.3 million ($0.02 per share), an increase from $2.4 million in the same quarter last year. Research and development expenses surged 268%, totaling $3.9 million due to a milestone expense. However, cash reserves improved to $29.1 million from $510,586 at the end of 2019, aided by several equity offerings totaling $54 million. Zomedica aims to enhance its TRUFORMA™ diagnostic platform with ongoing validations and strong partnerships.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced the appointment of Robert Cohen as a member of the Board of Directors, alongside Christopher Wolfenberg from Fasken Martineau DuMoulin LLP. Cohen joined Zomedica in June 2020, bringing over 20 years of experience in medical devices and biotechnology. The company is preparing for its Annual and Special Virtual-Only Meeting on September 25, 2020, where shareholders will ratify amendments to the by-laws facilitating electronic meetings and voting.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) announced the resignation of Shameze Rampertab as Chief Financial Officer, effective August 14, 2020. Ann Cotter, CPA, currently the Vice President of Finance, will serve as interim CFO. Cotter has extensive experience in accounting and finance, having worked in various roles since August 2018. CEO Robert Cohen expressed gratitude for Rampertab's four years of service and looks forward to working with Cotter as the company prepares for the commercial release of its TRUFORMA™ platform, aimed at addressing unmet needs in veterinary diagnostics.

Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) has successfully implemented the first remote installations of its TRUFORMA™ diagnostic device, facilitating validation testing with partner universities despite COVID-19 challenges. The device, designed for veterinary point-of-care diagnostics, recently completed verification for canine cortisol testing and plans to add more assays. Interim CEO Robert Cohen emphasizes the company's commitment to bringing TRUFORMA to market promptly, highlighting its innovative technology and the dedication of its team.